Indian biotech startup Pandorum Technologies raises $18 million in funding to scale operations

Pandorum Technologies, a biotechnology startup working in programmable regenerative medicine, has closed a $18 million Series B funding round to advance the clinical development of its disease-modifying, tunable, exosome-based therapies, including Kuragenx, while scaling global manufacturing and expanding operations across the US, Japan, and the Middle East.

The round was led by Protons Corporate, with participation from Galentic Pharma, investor Ashish Kacholia, Noblevast Advisory and Avinya Fund, the Burman Family, and other backers. Bandana Kankani, advisor and investor at Pandorum, guided the transaction and worked on aligning the investment structure with the company’s long-term value creation plans.

Founded by Tuhin Bhowmick and Arun Chandru, the Bengaluru-based startup operates across India and the United States. Pandorum’s proprietary platform combines biology, engineering, and computation to develop tunable, regenerative exosome therapies that reprogram pathological tissue states, like inflammation and fibrosis, toward functional recovery.

“Just like the Ship of Theseus, the human body is constantly being rebuilt. Pandorum focuses on restoring biological memory, redefining regenerative medicine at its core,” said Tuhin Bhowmick, co-founder and CEO.

“Our approach treats tissue health, disease, and degeneration as a navigational challenge within an information-constrained biological landscape. This funding would enable us to translate breakthrough science into programmable, disease-modifying therapies, beginning with single-tissue applications and scaling to multi-tissue repair, aligned with Pandorum’s vision to heal fast and age slow.”

Pandorum has adopted a globally distributed manufacturing strategy, including a CDMO partnership with AGC Biologics in Italy to serve the US and European markets, and a strategic collaboration with Nucelion Therapeutics, a subsidiary of Bharat Biotech, to support supply across the Asia-Pacific region. The startup is also exploring potential partnerships in the Middle East.

Clinical translation efforts are being led by clinicians including Dr. Virender Singh Sangwan of Dr. Shroff’s Charity Eye Hospital in New Delhi, Dr. Shigeru Kinoshita of Kyoto Prefectural University of Medicine, and Dr. Ramez Haddadin and Dr. Satish Nadig of Northwestern Medicine in Chicago.